Calgary, Alberta - TheNewswire - – June 3, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that it has set June 26, 2025 as the date for its first-in-human (FIH) clinical study.

 

The FIH clinical study involves the implantation of the Company’s inaugural accommodating intraocular lens (the “Ocumetics Lens”) in the first group of study patients at a designated clinic in Mexico City.  This milestone marks a historic moment for Ocumetics - culminating nearly two decades of relentless innovation, research, and development.

 

Dean Burns, CEO of Ocumetics, expressed the Company’s excitement, “June 26, 2025 will be a landmark day not just for Ocumetics, but for the entire field of ophthalmology. The implantation of our accommodating intraocular lenses in the first group of patients is the culmination of over 18 years of vision, planning, engineering, and perseverance.  The Ocumetics Lens represents a potential new frontier in sight restoration, and we are honored to take this next step with our clinical partners in Mexico City.”

For the first time in its 18-year history, Ocumetics will see its breakthrough accommodating intraocular lens implanted in human subjects, setting the stage for a new era in vision restoration.  The Ocumetics Lens is designed to restore the eye’s natural ability to shift focus from distance to near and back again, offering a potential paradigm shift in vision correction.

The study will be conducted in collaboration with the Company’s regulatory research consultants, whose expertise has been instrumental in ensuring readiness at the proposed site in Mexico City.  The targeted FIH implantation date was set after consideration of lens manufacturing and testing procedures, study site preparation, staff training, regulatory application submission, and approval timelines.

Dr. Garth Webb, Founder and CSO added: “This clinical trial is a significant moment for ophthalmic medical innovation.  Our team is proud to witness this historic step forward, and are fully prepared to facilitate a smooth study launch.”

With this critical milestone in sight, Ocumetics moves one step closer to demonstrating the safety and performance of the Ocumetics Lens in a real-world clinical setting - laying the groundwork for future regulatory submissions and readiness for commercial distribution.

 

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients.  Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.  

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

 

Dean Burns                                Roger Jewett

President and CEO                        Chief Financial Officer

(817) 874-7564                                roger.jewett@ocumetics.com

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.